Health, Bencini (Menarini Stemline Italia): “Proud of our commitment to oncohematology”

“As the Menarini Group we are proud to have undertaken this path of commitment to the research and development of drugs in the oncology-hematology field. Today we are here to share the recent approval by the Italian Medicines Agency of a new first-in-class molecule for the treatment of multiple myeloma: selinexor”. Thus Nicola Bencini, general manager of Menarini Stemline Italia, on the occasion of the press conference with which the pharmaceutical company announced the green light from Aifa for the reimbursement of selinexor, a selective oral inhibitor of the XPO1 protein, in association with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The meeting was an opportunity to also talk about another therapeutic option, the first specific therapy for blastic plasmacytoid dendritic cell neoplasia: tagraxofusp.